TEL-AVIV, Israel and RALEIGH, N.C., Aug 1 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock
Exchange:RDHL) (“RedHill” or the “Company”), a specialty
biopharmaceutical company primarily focused on late clinical-stage
development and commercialization of proprietary, orally-administered,
small molecule drugs for gastrointestinal and inflammatory diseases and
cancer, today reported, following a second pre-planned meeting to assess
the safety and efficacy data from its ongoing first Phase III study
with RHB-104 for Crohn’s disease (the MAP US study) by an independent
Data and Safety Monitoring Board (DSMB), that it has received a
unanimous positive recommendation from the DSMB to continue the study as
planned.
The independent DSMB reviewed safety
and efficacy data, of which RedHill remains blinded, from the first 222
subjects who have completed week 26 assessments in the Phase III MAP US
study. In December 2016, a first pre-planned independent DSMB meeting
reviewed safety data from the MAP US study and provided a unanimous
recommendation to continue the study as planned.
SOURCE : RedHill Biopharma Ltd.
No comments:
Post a Comment